Role of Non-Coding RNAs in the Development of Targeted Therapy and Immunotherapy Approaches for Chronic Lymphocytic Leukemia

Felice Pepe; Veronica Balatti

doi:10.3390/jcm9020593

Role of Non-Coding RNAs in the Development of Targeted Therapy and Immunotherapy Approaches for Chronic Lymphocytic Leukemia

J Clin Med. 2020 Feb 21;9(2):593. doi: 10.3390/jcm9020593.

Authors

Felice Pepe^{1

2}, Veronica Balatti^{1

2}

Affiliations

¹ Department of Cancer Biology and Medical Genetics, The Ohio State University, Columbus, OH 43210, USA.
² The Ohio State University Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA.

Abstract

In the past decade, novel targeted therapy approaches, such as BTK inhibitors and Bcl2 blockers, and innovative treatments that regulate the immune response against cancer cells, such as monoclonal antibodies, CAR-T cell therapy, and immunomodulatory molecules, have been established to provide support for the treatment of patients. However, drug resistance development and relapse are still major challenges in CLL treatment. Several studies revealed that non-coding RNAs have a main role in the development and progression of CLL. Specifically, microRNAs (miRs) and tRNA-derived small-RNAs (tsRNAs) were shown to be outstanding biomarkers that can be used to diagnose and monitor the disease and to possibly anticipate drug resistance and relapse, thus supporting physicians in the selection of treatment regimens tailored to the patient needs. In this review, we will summarize the most recent discoveries in the field of targeted therapy and immunotherapy for CLL and discuss the role of ncRNAs in the development of novel drugs and combination regimens for CLL patients.

Keywords: CLL; immunotherapy; mir-15/16; targeted therapy; venetoclax.

Publication types

Review